Webcast Alert: Aastrom to Host VEITHsymposium(TM) Satellite Event
ANN ARBOR, Mich., Nov. 11, 2010 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM) announces the following webcast:
| What: | Aastrom will present data from an interim analysis of its Phase 2b RESTORE-CLI clinical trial at a |
| VEITHsymposium™ non-CME satellite session. This event will include a webcast presentation | |
| by Dr. Richard Powell, RESTORE-CLI principal investigator, and a Q&A session with | |
| Dr. Powell, co-principal investigator, Dr. William Marston, CEO Tim Mayleben and | |
| Dr. Sharon Watling, vice president of clinical and regulatory at Aastrom. | |
| When: | Thursday, November 18, 2010 @ 1:00 pm (ET) |
| Where: | http://www.aastrom.com/investor.cfm |
| How: | • The conference call will be available live in the Investors section of Aastrom's website |
| at http://www.aastrom.com/investor.cfm. Please access the site at least 15 minutes | |
| prior to the scheduled start time in order to download the required audio software | |
| if necessary (RealPlayer or Windows Media Player). | |
| • To participate in the live call by telephone, please call (877) 312-5881 and reference | |
| Aastrom's RESTORE-CLI update conference call. If calling from outside the U.S., please | |
| use the international phone number (253) 237-1173. | |
| • A podcast will also be available after the live event at http://www.aastrom.com/events.cfm. |
If you are unable to participate during the live call, the webcast will be available for replay at http://www.aastrom.com/events.cfm for up to 90 days. A replay of the call will also be available until 12:00 am (ET) on Thursday, November 25, 2010 by calling (800) 642-1687, or from outside the U.S. at (706) 645-9291. The passcode for the replay is 24654952.
About Aastrom Biosciences
Aastrom Biosciences is an emerging biotechnology company developing expanded autologous cellular therapies for use in the treatment of severe cardiovascular diseases. The company's proprietary cell-processing technology enables the production of cellular therapies expanded from a patient's own bone marrow and delivered directly to damaged tissues. Aastrom has advanced its cell therapies into late-stage clinical development, including a planned Phase 3 clinical program for the treatment of patients with critical limb ischemia and two ongoing Phase 2 clinical trials in patients with dilated cardiomyopathy. For more information, please visit Aastrom's website at www.aastrom.com.
The Aastrom Biosciences, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=3663
CONTACT: Berry & Company
Media Contact
Stephen Zoegall
212 253-8881
szoegall@berrypr.com
Aastrom Biosciences
Investor Contact
Kimberli O'Meara
734 930-5777
ir@aastrom.com